Bioavailability Enhancement with Lipid-Based Formulation

Abstract: Lipid-Based Formulation has been steadily growing in the industry for the past few decades since the launch of Sandimmune in 1983. To date we have growing number of drugs formulated with lipidic excipients with the aim of improving the bioavailability enhancement. This is especially urgent considering a vast number of drugs in development are currently of BCS Class II or IV. Self-Microemulsifying Drug Delivery System (SMEDDS), although known in the academia and the industry, is gaining traction as one of the simplest methods to improve bioavailability enhancement. Unfortunately, the exact development process from excipient selection to correct characterization of such formulation still eludes many in the industry.

Biography: This talk will feature Dr. Nabil Farah, the Technical Director of Gattefosse. Dr. Farah has been developing lipidic formulations since 1990 at Gattefosse, a private company based in Lyon, France, and a leader in functional lipid excipient supplies for the pharmaceutical industry, est. 1880. He is the inventor and owner of patents in sustained release technology using lipids, SMEDDS technology, microemulsion technology, and hot melt coating technology, with professional membership in APGI, SFSTP, CRS, and AAPS.